ERBB2 and breast cancer: Subsequently, a study of BC patients enrolled in the BIG 02-98 adjuvant clinical trial revealed that patients with lymphocyte predominant BC, primarily the HER2+ and TN subtypes, have the best long-term clinical outcomes [7].